Top Markets
#1 Wiki Cat Wiki Cat +26.34%
#2 Ribbita by Virtuals Ribbita by Virtuals +19.03%
#3 Bitway Bitway +18.16%
#4 PulseChain PulseChain +16.92%
#5 Velvet Velvet +16.49%
#6 TRIA TRIA +16.19%
#7 Cysic Cysic +16.06%
#8 Siren Siren +14.04%
#9 KUB Coin KUB Coin +13.60%
#10 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +13.59%
Coin of the day
Wiki Cat Wiki Cat
सेटिंग्स
भाषा
हिन्दी
मुद्रा
USD
थीम
Clovis Oncology, Inc. Clovis Oncology, Inc.

Clovis Oncology, Inc.

C6O
शेयरों में रैंक #30761
Clovis Oncology, Inc. is a biopharmaceutical company focused on the discovery,... Clovis Oncology, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of anti-cancer agents, serving markets in the United States, Europe, and globally. Its flagship commercial product in the U.S. is Rubraca (rucaparib), an oral small molecule designed to inhibit poly ADP-ribose polymerase. This treatment is indicated for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, Rubraca is offered for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. The company's pipeline includes lucitanib, an investigational angiogenesis inhibitor that targets vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3). Also under development is FAP-2286, an investigational peptide-targeted radionuclide therapy and imaging agent that specifically acts upon fibroblast activation protein. Rubraca is distributed through a select network of specialty distributors and pharmacies, which then supply the medication to patients and healthcare providers. Clovis Oncology has established strategic collaborations, including license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH. The company also maintains a clinical collaboration with Bristol Myers Squibb Company and a partnership with Foundation Medicine, Inc. Founded in 2009, Clovis Oncology, Inc. is headquartered in Boulder, Colorado.
शेयर मूल्य
$0.10794012
अंतिम समन्वयन: 2022-12-15
मार्केट कैप
$15.65M
बदलाव (1 दिन)
-17.06%
बदलाव (1 वर्ष)
0.00%
देश
US
व्यापार Clovis Oncology, Inc. (C6O)

श्रेणी

Healthcare
Clovis Oncology, Inc. (C6O) के लिए बकाया शेयरों की संख्या
August 2026 की स्थिति में बकाया शेयरों की संख्या: 0
Clovis Oncology, Inc. की नवीनतम वित्तीय रिपोर्ट और शेयर मूल्य के अनुसार, कंपनी के वर्तमान बकाया शेयरों की संख्या 0 है। August 2026 के अंत में कंपनी के पास 0 बकाया शेयर थे। बकाया शेयरों की संख्या आमतौर पर शेयर स्प्लिट्स और शेयर बायबैक से प्रभावित होती है।
Clovis Oncology, Inc. (C6O) के लिए 2026 से 2026 तक बकाया शेयरों का इतिहास
प्रत्येक वर्ष के अंत में बकाया शेयर
वर्ष बकाया शेयर परिवर्तन
प्रदान की गई तारीखों के लिए पर्याप्त डेटा नहीं।
समान कंपनियों या प्रतिस्पर्धियों के लिए बकाया शेयर
कंपनी बकाया शेयर अंतर देश
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 483.58M -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 0.00 -
BE